HC Wainwright Lowers DBV Technologies (NASDAQ:DBVT) Price Target to $5.00

DBV Technologies (NASDAQ:DBVT) had its price target reduced by research analysts at HC Wainwright from $10.00 to $5.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, StockNews.com initiated coverage on shares of DBV Technologies in a report on Monday. They issued a “hold” rating for the company.

DBV Technologies Stock Down 17.8 %

NASDAQ:DBVT opened at $0.57 on Wednesday. DBV Technologies has a 52 week low of $0.56 and a 52 week high of $2.37. The stock’s fifty day moving average is $0.74 and its two-hundred day moving average is $0.84. The stock has a market capitalization of $110.03 million, a price-to-earnings ratio of -1.46 and a beta of 0.73.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. The firm had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative return on equity of 46.33% and a negative net margin of 461.32%. During the same quarter in the prior year, the company earned ($0.23) EPS. On average, sell-side analysts expect that DBV Technologies will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds have recently bought and sold shares of the stock. Optiver Holding B.V. grew its position in shares of DBV Technologies by 595.2% during the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after buying an additional 235,337 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in DBV Technologies in the third quarter worth approximately $94,000. Finally, Cowen AND Company LLC acquired a new position in DBV Technologies during the 4th quarter worth approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.